Anthony Sireci, MD, MSc, Senior Vice President of Clinical Biomarkers, Laboratories and Diagnostics for Eli Lilly and Company, also known as “Nino,” is a Clinical Pathologist and recognized leader in integrating advanced diagnostics into drug development and clinical practice to identify patients who can benefit from personalized medicines.
Nino has spoken and written broadly about precision oncology, emphasizing the role of timely and comprehensive biomarker testing in ensuring that cancer patients are matched with the most effective therapies available. In his current position, he is also focused on emerging areas of personalized medicine beyond oncology, particularly the use of new blood-based technologies to detect amyloid pathology in patients with early Alzheimer’s disease.
In his time at Loxo@Lilly Oncology and in his current leadership role, Nino has led efforts to integrate clinical biomarkers and diagnostics across oncology drug development and clinical practice. He’s also served as an assistant professor of pathology and cell biology at Columbia University and a medical director in the @Laboratory of Personalized Genomic Medicine at Columbia Medical Center.
He is an active member of the Association for Molecular Pathology (AMP) where he serves on the organization’s strategy committee and was the former vice chair for new codes and pricing on the economic affairs committee.